Lies, Damn Lies, And DTC Ads?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Risk Communications Advisory Committee is set to discuss how quantitative risk information can be presented in such a way as to inform rather than mislead consumers.
You may also be interested in...
Risk Communications Panel To Discuss Public Confusion, “Message Fatigue”
FDA advisory committee will again consider whether consumers have an inaccurate understanding of drug risks or are so overwhelmed by messages about them that they discount the warnings.
FDA To Study Impact Of Rx Drug Ads That Provide Disease Information
The agency plans to assess whether the inclusion of disease information in an Rx drug print ad affects consumer perception about the product.
Adverse Events, Direct From The Consumer
FDA's proposed consumer version of the MedWatch form for reporting drug-related adverse events goes before an advisory panel.